Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients
A Randomized, Controlled, Multicenter Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients
Sponsor: Beijing Shijitan Hospital, Capital Medical University
A PHASE2 clinical study on Neurotoxicity, this trial is ongoing. The trial is conducted by Beijing Shijitan Hospital, Capital Medical University and has accumulated 10 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Oct 2021 — Nov 2022 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Unknown Status PHASE2
▶ Show 5 earlier versions
-
Jan 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Aug 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Shijitan Hospital, Capital Medical University
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Chinese PLA General Hospital
- Peking Union Medical College Hospital
- Peking University Cancer Hospital & Institute
- Peking University First Hospital
- Peking University Third Hospital
- Weifang People's Hospital
- Yantai Yuhuangding Hospital
For direct contact, visit the study record on ClinicalTrials.gov .